Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma

✍ Scribed by Jonathan W. Friedberg; Annick D. Van den Abbeele; Kathleen Kehoe; Samuel Singer; Christopher D. Fletcher; George D. Demetri

• Book ID: 101230806
• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 198 KB
• Volume: 86
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19991015)86:8<1621::aid-cncr33>3.0.co;2-m

✦ Synopsis

BACKGROUND.

Somatostatin receptors are present on many types of epithelial tumors, and ligands targeting these receptors are used to treat patients with neuroendocrine malignancies. Preclinical studies have demonstrated the presence of somatostatin receptors on a variety of mesenchymal tumors by in vitro receptor autoradiography. The use of radiolabeled somatostatin analogs to assess the presence of somatostatin receptors in vivo has been established, but use of this technique to evaluate human sarcomas has not been reported previously.

METHODS.

Seventeen patients (13 females and 4 males) with metastatic sarcoma underwent imaging via somatostatin-receptor scintigraphy. Scans were performed using indium -111 pentetreotide. Planar studies and single photon emission computed tomography imaging were performed at 4 and 24 hours, and results of scintigraphy were correlated with computed tomography findings.